Literature DB >> 8134380

Secretion of human hepatitis B virus is inhibited by the imino sugar N-butyldeoxynojirimycin.

T M Block1, X Lu, F M Platt, G R Foster, W H Gerlich, B S Blumberg, R A Dwek.   

Abstract

The imino sugar N-butyldeoxynojirimycin (NBDNJ) is a potent inhibitor of the oligosaccharide-trimming enzyme alpha-glucosidase I. Hepatitis B virus (HBV) contains three surface proteins (HBs proteins) of different sizes that are singly or doubly N-glycosylated and are essential for the formation of infectious virus. Therefore, the replication and secretion of HBV in the human hepatoma cell line HepG2 were studied in the presence of NBDNJ. In the stably HBV-transfected HepG 2.2.15 cells and in HBV-infected HepG2 cells, NBDNJ suppressed secretion of HBV particles and caused intracellular retention of HBV DNA. The secretion of subviral particles was less affected. These data suggest that inhibitors of oligosaccharide trimming may be useful for antiviral therapy of hepatitis B and for the study of the intracellular transport of the viral glycoproteins.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8134380      PMCID: PMC43345          DOI: 10.1073/pnas.91.6.2235

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  24 in total

1.  Immunogenicity of the gene S and Pre-S domains in hepatitis B virions and HBsAg filaments.

Authors:  K H Heermann; F Kruse; M Seifer; W H Gerlich
Journal:  Intervirology       Date:  1987       Impact factor: 1.763

Review 2.  Treatment of chronic hepatitis B with interferon: experience in western countries.

Authors:  R P Perrillo
Journal:  Semin Liver Dis       Date:  1989-11       Impact factor: 6.115

3.  The use of polyvinylidenedifluoride membranes as a general blotting matrix.

Authors:  H Gültekin; K H Heermann
Journal:  Anal Biochem       Date:  1988-08-01       Impact factor: 3.365

Review 4.  Therapy of chronic viral hepatitis: past, present, and future.

Authors:  J H Hoofnagle; E A Jones
Journal:  Semin Liver Dis       Date:  1989-11       Impact factor: 6.115

5.  In vitro and in vivo comparison of the abilities of purine and pyrimidine 2',3'-dideoxynucleosides to inhibit duck hepadnavirus.

Authors:  B Lee; W X Luo; S Suzuki; M J Robins; D L Tyrrell
Journal:  Antimicrob Agents Chemother       Date:  1989-03       Impact factor: 5.191

6.  Inhibition of the replication of hepatitis B virus by the carbocyclic analogue of 2'-deoxyguanosine.

Authors:  P M Price; R Banerjee; G Acs
Journal:  Proc Natl Acad Sci U S A       Date:  1989-11       Impact factor: 11.205

7.  Evaluation of the role of rat liver Golgi endo-alpha-D-mannosidase in processing N-linked oligosaccharides.

Authors:  W A Lubas; R G Spiro
Journal:  J Biol Chem       Date:  1988-03-15       Impact factor: 5.157

8.  Replication of hepatitis B virus in transfected nonhepatic cells.

Authors:  M Seifer; K H Heermann; W H Gerlich
Journal:  Virology       Date:  1990-11       Impact factor: 3.616

9.  Aminosugar derivatives as potential anti-human immunodeficiency virus agents.

Authors:  A Karpas; G W Fleet; R A Dwek; S Petursson; S K Namgoong; N G Ramsden; G S Jacob; T W Rademacher
Journal:  Proc Natl Acad Sci U S A       Date:  1988-12       Impact factor: 11.205

10.  Inhibition of HIV replication by amino-sugar derivatives.

Authors:  G W Fleet; A Karpas; R A Dwek; L E Fellows; A S Tyms; S Petursson; S K Namgoong; N G Ramsden; P W Smith; J C Son
Journal:  FEBS Lett       Date:  1988-09-12       Impact factor: 4.124

View more
  49 in total

1.  Alpha-glucosidase inhibitors reduce dengue virus production by affecting the initial steps of virion morphogenesis in the endoplasmic reticulum.

Authors:  M P Courageot; M P Frenkiel; C D Dos Santos; V Deubel; P Desprès
Journal:  J Virol       Date:  2000-01       Impact factor: 5.103

Review 2.  The endoplasmic reticulum protein folding factory and its chaperones: new targets for drug discovery?

Authors:  Martin McLaughlin; Koen Vandenbroeck
Journal:  Br J Pharmacol       Date:  2011-01       Impact factor: 8.739

3.  Combination of α-glucosidase inhibitor and ribavirin for the treatment of dengue virus infection in vitro and in vivo.

Authors:  Jinhong Chang; Wouter Schul; Terry D Butters; Andy Yip; Boping Liu; Anne Goh; Suresh B Lakshminarayana; Dominic Alonzi; Gabriele Reinkensmeier; Xiaoben Pan; Xiaowang Qu; Jessica M Weidner; Lijuan Wang; Wenquan Yu; Nigel Borune; Mark A Kinch; Jamie E Rayahin; Robert Moriarty; Xiaodong Xu; Pei-Yong Shi; Ju-Tao Guo; Timothy M Block
Journal:  Antiviral Res       Date:  2010-11-10       Impact factor: 5.970

4.  Tea polyphenols exerts anti-hepatitis B virus effects in a stably HBV-transfected cell line.

Authors:  Pian Ye; Shuling Zhang; Lei Zhao; Jihua Dong; Shenghua Jie; Ran Pang; Shuli Li
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2009-04-28

5.  Selective inhibition of the duck hepatitis B virus by a new class of tetraazamacrocycles.

Authors:  O Hantz; C Borel; C Trabaud; F Zoulim; J Dessolin; M Camplo; P Vlieghe; M Bouygues; C Trepo; J L Kraus
Journal:  Antimicrob Agents Chemother       Date:  1997-11       Impact factor: 5.191

6.  Antiviral effects of an iminosugar derivative on flavivirus infections.

Authors:  Shu-Fen Wu; Chyan-Jang Lee; Ching-Len Liao; Raymond A Dwek; Nicole Zitzmann; Yi-Ling Lin
Journal:  J Virol       Date:  2002-04       Impact factor: 5.103

7.  Hepatitis B virus large and middle glycoproteins are degraded by a proteasome pathway in glucosidase-inhibited cells but not in cells with functional glucosidase enzyme.

Authors:  Ender Simsek; Anand Mehta; Tianlun Zhou; Raymond A Dwek; Timothy Block
Journal:  J Virol       Date:  2005-10       Impact factor: 5.103

8.  The alpha-glucosidase inhibitor N-butyldeoxynojirimycin inhibits human immunodeficiency virus entry at the level of post-CD4 binding.

Authors:  P B Fischer; M Collin; G B Karlsson; W James; T D Butters; S J Davis; S Gordon; R A Dwek; F M Platt
Journal:  J Virol       Date:  1995-09       Impact factor: 5.103

9.  Protease-induced infectivity of hepatitis B virus for a human hepatoblastoma cell line.

Authors:  X Lu; T M Block; W H Gerlich
Journal:  J Virol       Date:  1996-04       Impact factor: 5.103

Review 10.  Targeting hepatitis B therapy to the liver. Clinical pharmacokinetic considerations.

Authors:  P C Rensen; R L de Vrueh; T J van Berkel
Journal:  Clin Pharmacokinet       Date:  1996-08       Impact factor: 6.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.